Addiction to B-MYB

por Gustafson, W. Clay, Weiss, William A.
Publicado 2010

A new “angle” on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition

por Meyerowitz, Justin G, Weiss, William A, Gustafson, W Clay
Publicado 2015

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer

por Cage, Tene Aneka, Chanthery, Yvan, Chesler, Louis, Grimmer, Matthew, Knight, Zachary, Shokat, Kevan, Weiss, William A., Gustafson, W. Clay
Publicado 2015

GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion–positive rhabdomyosarcoma

por Morales, Jacqueline, Allegakoen, David V., Garcia, José A., Kwong, Kristen, Sahu, Pushpendra K., Fajardo, Drew A., Pan, Yue, Horlbeck, Max A., Weissman, Jonathan S., Gustafson, W. Clay, Bivona, Trever G., Sabnis, Amit J.
Publicado 2022

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

por Yi, Joanna S., Sias-Garcia, Oscar, Nasholm, Nicole, Hu, Xiaoyu, Iniguez, Amanda Balboni, Hall, Matthew D., Davis, Mindy, Guha, Rajarshi, Moreno-Smith, Myrthala, Barbieri, Eveline, Duong, Kevin, Koach, Jessica, Qi, Jun, Bradner, James E., Stegmaier, Kimberly, Weiss, William A., Gustafson, W. Clay
Publicado 2021